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Abstract
Background—The pharmacokinetics (PK) of antiretrovirals (ARVs) in older HIV-infected
patients are poorly described. Here, the steady-state PK of 2 common ARV regimens (tenofovir
[TFV]/emtricitabine [FTC]/efavirenz [EFV]; TFV/FTC/atazanavir [ATV]/ritonavir [RTV]) in
older non-frail HIV-infected patients are presented.
Methods—HIV-infected subjects ≥ 55 years old not demonstrating the frailty phenotype were
enrolled in an unblinded, intensive-sampling PK study. Blood plasma (for TFV, FTC, EFV, ATV,
and RTV concentrations) and peripheral blood mononuclear cells (PBMCs; for tenofovir
diphosphate [TFV-DP] and emtricitabine triphosphate [FTC-TP] concentrations) were collected at
11 time points over a 24-hour dosing interval. Drug concentrations were analyzed using validated
LC-UV or LC-MS/MS methods. Noncompartmental pharmacokinetic analysis was used to
estimate PK parameters (AUC0–24hr, Cmax). These parameters were compared to historical values
from the general HIV-infected population.
Results—Six subjects on each regimen completed the study. Compared to the general
population, these elderly subjects had 8–13% decreased TFV AUC0–24hr and Cmax, and 19–78%
increased FTC and RTV AUC0–24hr and Cmax. Decreased ATV AUC0–24hr (12%) and increased
Cmax (9%) were noted, while EFV exposure was unchanged (5%) with a 16% decrease in Cmax.
Intracellular nucleoside/tide metabolite concentrations and AUC are also reported for these
subjects.
Conclusions—This study demonstrates that the PK of these ARVs are altered by 5–78% in an
older HIV-infected population. Implications of PK differences on clinical outcomes, particularly
with the active nucleoside metabolites, remain to be explored. This study forms the basis for
further study of ARV PK, efficacy, and toxicity in older HIV-infected patients.
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As a direct result of improved antiretroviral (ARV) treatment, patients with chronic HIV
infection in the United States are living longer. As such, non-AIDS related diseases are an
increased cause of death (1). From 2006 to 2009, the 60–64 year age group saw the largest
increases in patients living with HIV/AIDS with the largest age demographic in the 44–49
(19%) age group (2). These numbers will continue to increase as life expectancy increases.
An estimated one-half of those living with HIV will be >50 years old by 2015 (2).
Although older HIV-infected adults typically demonstrate excellent virologic response to the
initiation of antiretroviral therapy (3, 4), immunologic recovery is frequently diminished
compared to younger patients (3, 5), with a slower and blunted recovery of CD4+ cells after
ARV initiation. This results in increased mortality and an overall worse prognosis. Every 10
years of additional chronological age provides 35 fewer CD4+ cells/μL during a year of
treatment (6, 7). Advanced disease at diagnosis (4) and senescence may partially explain this
phenomenon. However, the contribution of altered ARV PK and the resultant risk for
adverse events has not been investigated.
Known physiologic changes during aging can affect drug absorption, distribution,
metabolism, and excretion, and these changes have been shown to affect clinical outcomes
(8, 9). However, little is known about these effects on the PK of ARVs used to treat this
growing population of HIV-infected patients. Modest evidence suggests that cellular
activation, such as that seen with aging and HIV infection, may increase intracellular
phosphorylase activity in the elderly (10), potentially resulting in increased toxicity of
nucleoside reverse transcriptase inhibitors (NRTIs) (11). The active intracellular
phosphorylated forms of tenofovir and emtricitabine, two such agents, have not been studied
in older patients (12–14).
The present investigation sought to characterize the PK of two common, first-line ARV
regimens in HIV-infected patients ≥55 years old in order to provide PK parameter estimates
for optimal sample design for a population pharmacokinetic/pharmacodynamic (PK/PD)
investigation of the effects of aging on ARVs.
Methods
Study Design and Population
Twelve HIV-infected adults ≥ 55 years old were recruited from the University of North
Carolina (UNC) Healthcare Infectious Diseases Clinic in Chapel Hill, NC. The protocol was
approved by the UNC Biomedical Institutional Review Board and the protocol listed on
ClinicalTrials.gov (NCT01180075). Six currently adherent subjects for each of two
regimens: either TFV 300mg/FTC 200mg/EFV 600mg administered once daily (Atripla™,
Bristol-Myers Squibb, New York, NY) or TFV 300mg/FTC 200mg (Truvada™, Gilead
Sciences, Foster City, CA), ATV 300mg (Reyataz™, Bristol-Myers Squibb, New York,
NY), and RTV 100mg (Norvir™, Abbott Laboratories, Chicago, IL) administered once daily
provided informed consent and underwent screening. This was a convenience sample,
selected to provide preliminary PK information for future work. Adherence was defined as
≤3 missed doses in the previous 30 days, with no missed doses in the 3 days immediately
preceding pharmacokinetic sampling. Subjects received their regimen for at least 2 weeks
prior to sample collection. Screening consisted of vital signs, a physical exam, basic
laboratory studies (performed within 45 days of enrollment), and frailty phenotyping. Frailty
phenotyping was performed as in Fried et al (15) by the Clinical and Translational Research
Center Bionutrition Core at UNC, and includes answering questions regarding unintentional
weight loss, fatigue, and physical activity, in addition to measuring grip strength and walk
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times. Subjects with unstable vital signs, abnormal lab values meeting DAIDS Grade 1
anemia (hemoglobin < 8.5 mg/dL) or DAIDS Grade 2 criteria for other lab abnormalities, or
displaying the frailty phenotype were excluded. Cognitive status was not assessed and
cognitive impairment was not an exclusion criteria. For subjects receiving ATV, Grade 2
total bilirubin elevations (up to 2.5 times the upper limit of normal) were allowed, with
clinical documentation that the elevation was related to ATV administration and clinically
insignificant. Subjects receiving concomitant medications expected to alter the PK
parameters of a study drug ≥30% were excluded; subjects receiving ATV were excluded for
concomitant proton pump inhibitor or a histamine-2 receptor inhibitor therapy.
PK Visit
Subjects were admitted to the NC TraCS Institute Clinical and Translational Research
Center (CTRC) approximately 2 hours prior to their home dosing time of the ARV regimen
for vital signs, a complete blood count (CBC) to check for anemia prior to sampling, a brief
physical exam, and adherence questioning. Subjects also completed dosing cards for the 3
days prior to their PK visit, and cards were reviewed by study personnel at admission. Blood
samples were was collected in K2EDTA tubes (BD Diagnostics, Franklin Lakes, NJ) for
plasma processing and CPT tubes (BD Diagnostics, Franklin Lakes, NJ) for peripheral blood
mononuclear cells (PMBCs) at −0.5, 0.5, 1, 2, 3, 4, 6, 8, 12, 18, and 24 hours following a
witnessed dose. Subjects receiving TFV/FTC/EFV took their dose on an empty stomach and
did not eat for at least 4 hours post-dose; TFV/FTC/ATV/RTV subjects took their dose with
a standard research meal at their typical time of medication administration. A whole blood
sample was also obtained for future pharmacogenomic analyses. Adverse event
questionnaires(16) were administered prior to discharge. Subjects returned for a brief
follow-up visit within 30 days of the PK visit which included vital signs, a CBC, a brief
physical exam, and adverse event questionnaires.
Sample Collection and Processing
Within 1 hour after collection, K3EDTA tubes stored on ice were processed by
centrifugation at 3000×g at 4°C for 10 minutes. The resultant plasma was aliquoted into
labeled cryovials, and stored at −80°C until analysis. Within 2 hours after collection, CPT
tubes stored at room temperature were centrifuged at 1300×g for 30 minutes at room
temperature with the brake off. After washing the gel with cold 0.9% normal saline, the
PBMC-containing plasma was centrifuged at 350×g for 10 minutes at 4°C. After discarding
the supernatant, cells were resuspended in red blood cell lysis buffer and allowed to sit at
room temperature for 2 minutes. After adding 10mL cold 0.9% normal saline and
centrifugation at 300×g for 5 minutes at 4°C, cells were prepared for counting using Trypan
blue exclusion and a Countess Cell Counter. After counting, cells were lysed with 70:30
methanol:water solution, and the methanolic extracts obtained after 15 minutes on ice
followed by centrifugation at 800×g for 10 minutes at 4°C were stored at −80°C until
analysis.
Concentration Analysis
Tenofovir, emtricitabine, efavirenz, atazanavir, and ritonavir concentrations in plasma were
determined using validated HPLC-UV methods (17, 18). All methods were validated as
mandated by the industry guidance set by the US DHHS, FDA, and CDER (19). For all the
above analytes, the dynamic range is 10–10,000 ng/mL. Tenofovir diphosphate (TFV-DP)
and emtricitabine triphosphate (FTC-TP) concentrations were determined using validated
LC-MS/MS methods with an Agilent 1200 HPLC system connected to an Agilent 6410
triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA). Briefly,
methanolic extracts underwent protein precipitation with 1:1 methanol/1mM ammonium
phosphate solution containing the internal standards (13C TFV, 13C 15N FTC, 13C TFV-DP),
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followed by evaporation to dryness under nitrogen and reconstitution with 1mM ammonium
phosphate. The analytes were eluted from a Waters Xbridge™ C18 (2.1 × 20 mm, 5μm
particle size) analytical column (Waters Corporation, Milford, MA) in series with a Thermo
Scientific BioBasic AX (50 × 2.1mm 5μm particle size) column (Thermo Fisher Scientific,
Waltham, MA). Data were collected using Agilent LC-MS/MS MassHunter
Chromatography Software, with positive ion m/z transitions of 448.1/270.1 (TFV-DP) and
488.1/130 (FTC-TP) using electrospray ionization. The dynamic range of the assay is 1–
1,000 ng/mL; raw concentration values are normalized for cells counts and molecular mass
of the analyte, with final concentration values reported as femtomoles/106 cells. All
calibrators and quality controls samples were within 15% of the nominal value for both
within-day and between-day runs.
All drug concentrations were performed in the UNC Center for AIDS Research Clinical
Pharmacology and Analytical Chemistry Laboratory. The lab participates in national and
international proficiency testing of its methods, and consistently achieves >95% accuracy in
this testing.
Pharmacokinetic and Statistical Analysis
After preliminary graphical analysis, noncompartmental analysis for each drug was
performed using Phoenix Win Nonlin v6.1 (Pharsight, Inc; Cary, NC). The maximal
concentration (Cmax) and time of maximal concentration (Tmax) were determined from
visual inspection. Area-under-the-concentration-time curve over 24 hours (AUC) was
determined using the trapezoidal rule (linear up/log down interpolation). Terminal half-life
was calculated from the log-linear slope of the elimination phase. PK parameter estimates
for extracellular drugs (TFV, FTC, EFV, ATV, RTV) were compared to values reported
either in the drug's Full U.S. Prescribing Information or the literature. Due to the variable
nature of intracellular metabolite concentrations, AUC (linear trapezoidal rule) and average
PBMC concentrations across dosing intervals are presented.
To compare these results with published PK parameters for extracellular drugs in the general
HIV-infected population, the mean or median PK parameter available in the literature, that
as closely represented the study design and data analysis as possible, was used to calculate
ratios for Cmax (peak concentrations) and AUC (drug exposure) of older cohort:general
population. For each subject, the parameter of interest was divided by the literature value,
and the median ratio for all subjects is reported. Statistical comparisons were made using the
Wilcoxon Rank Sum test in SAS JMP7 (SAS Institute, Cary, NC) at a significance level of
α= 0.05. Due to differing sampling schemes and analytical methodologies between our
study and other published reports of TFV-DP and FTC-TP, statistical comparisons were not
made for these metabolites.
Results
Subject Demographics and Safety Evaluation
Twelve subjects were screened and enrolled. Demographic data for subjects by regimen are
presented in Table 1. Overall, the average age was 59.7 ± 3.9 years, BMI was 29.9 ± 5.4 kg/
m2, and CrCL was 70.1 ± 17.6 ml/min (mean/standard deviation). Equal numbers of
Caucasians and African Americans were enrolled on each regimen, and half of all subjects
were female. Eleven of twelve subjects had undetectable HIV RNA concentrations at
screening; 1 subject, who had initiated TFV/FTC/EFV within the last month, had a viral
load of 1372 copies/mL at screening which was <50 copies/mL 3 months later. Mean CD4+
lymphocyte counts were 818 ± 370 cells/mm3 for all subjects. Subjects reported no missed
doses, and all doses in the 3 days prior to the PK visit were taken within 3 hours of the
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scheduled administration time. With the exception of one TFV/FTC/ATV/RTV subject who
had a dose that was 1.5 hours late, all other doses immediately prior to the PK visit were
taken within 30 minutes of the scheduled administration time.
This cohort of older HIV-infected subjects tolerated intensive PK sampling well. No
subjects experienced significant changes in CBC values between sampling and follow-up.
One subject reported developing a sore throat that spontaneously resolved and deemed by
the study physician not to be related to the study intervention.
Noncompartmental Analysis
Concentration-time profiles for each drug are presented in Figure 1a–e. NCA parameter
estimates are reported in Table 2 for each drug in each regimen. TFV and FTC parameter
estimates are provided separately for each regimen. The terminal half-life and Tmax for FTC
were statistically different between regimens (p< 0.05); no statistically significant
differences were observed for TFV PK parameters by regimen (all p>0.05).
A summary of comparisons to historical values in the adult HIV-infected population for both
regimens is presented in Table 3. Compared to published values for TFV (20), FTC (21),
and EFV (22), several differences are noted. The AUC0-24hr and Cmax of TFV are slightly
lower in the TFV/FTC/EFV cohort, with a median ratio of 0.92 for AUC0-24hr and a median
ratio of 0.87 for Cmax. In contrast, the AUC0-24hr and Cmax of FTC were found to be higher
in our cohort, with a median ratio of 1.75 for AUC0-24hr and median ratio of 1.26 for Cmax.
For EFV, AUC0-24hr was similar to historic controls (median ratio of 1.05), with a lower
Cmax (median ratio of 0.84). These differences did not achieve statistical significance.
For the subjects receiving TFV/FTC/ATV/RTV, comparison to the same TFV (20)/FTC
(21) reference parameters indicates similar results for FTC (median ratios of 1.31 for both
AUC0-24hr and Cmax) and TFV (median ratio 0.90 for AUC0-24hr and 0.94 for Cmax). For
ATV/RTV co-administered with TFV at a dose of 300mg ATV + 100mg RTV (23), ATV
exposures in this cohort are lower (median ratio of 0.88 for AUC0-24hr) with a higher Cmax
(median ratio of 1.09). For RTV, higher AU0-24hr C and Cmax were seen, with a median
AUC0-24hr ratio of 1.19 and a median Cmax ratio of 1.78. These differences did not achieve
statistical significance.
Intracellular Metabolite Analysis
For TFV-DP, the median/IQR AUC0-24hr and the mean concentration over the dosing
interval by regimen are reported in Table 4. The comparator available in the literature (24)
included mean concentrations over the dosing interval, with a reported value of 76.1 fmol/
106 cells compared to 128 ± 78 fmol/106 cells (mean ± standard deviation) for EFV subjects
and 112 ± 78 fmol/106 cells for ATV/r subjects in this study, suggestinghigher TFV-DP
concentrations in older subjects.
Median/IQR AUC0-24hr and mean concentration over the dosing interval for FTC-TP are
also reported by regimen in Table 4. The comparator available in the literature (21) includes
the median 4-hr post-dose concentration, with a reported value of 4000 fmol//106 cells
compared to 3110 (2100, 4120) fmol/106 cells (median/IQR) for EFV subjects and 3100
(2389, 3346)) fmol/106 cells for ATV/r subjects in this study, suggesting lower FTC-TP
concentrations in older patients.
Discussion
In this PK study of 2 of the recommended first-line ARV regimens (25) in older HIV-
infected adults, noncompartmental PK parameters were similar to historic controls. ATV,
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EFV, and RTV all undergo significant CYP450-mediated metabolism, and liver mass is
known to decrease with age (26–28). Based on a population PK report, higher EFV
exposures were expected (29), potentially due to decreased auto-induction of EFV
metabolism through CYP3A, but was not seen in this small study of non-frail subjects ≥55
years. Owing to its acid-dependent absorption profile and the potential effects of altered
metabolism (30), decreased ATV exposures were expected. Although exposure was similar,
peak concentrations decreased, which may be explained by altered absorption (23, 30). RTV
concentrations and exposure did increase, however given the complicated PK profile of this
drug, it is not possible to determine what factors may be influencing this observation at this
time, and merits further exploration.
The observed difference between FTC terminal elimination half-life and Tmax in the TFV/
FTC/EFV and TFV/FTC/ATV/RTV regimens does not appear to be related to a drug-drug
interaction or differences in renal function between groups; although the mean creatinine
clearance value in the EFV group is lower, this is primarily driven by a single subject. TFV,
which is also renally cleared, shows similar trends, but exposure and peak concentrations
were lower. Both drugs are substrates for drug transporters (31), and the potential effects of
aging on drug transport activity has not been well categorized (32). A recent publication in
aged mice suggests both age-related and gender-specific changes in transporter expression
(33); these data offer a basis for further exploration of transporter effects on TFV and FTC
disposition.
This is one of the few studies to collect intensive PBMC samples and report TFV-DP and
FTC-DP values at 11 points over a 24 hour dosing regimen, and the first to look at these
metabolites specifically in the elderly population. The observed changes between
concentrations in the dosing interval compared to historical data may reflect differences in
the intracellular metabolic pathways for the drugs due to increased cellular activation in
older patients. FTC is preferentially metabolized in resting cells (34), whereas TFV may be
metabolized in either resting or activated cells (35). In the study used for comparison for
TFV-DP (24), a polymorphism in gene coding for MRP-4 and tenofovir renal clearance
were related to intracellular concentrations, suggesting that alterations in transporter activity
could contribute to altered TFV-DP concentrations in older patients.
As chronologic age alone may not adequately describe physiologic changes that occur with
disease processes, studying frail older individuals may provide new insight. Frailty is
described as a clinical syndrome of decreased functional reserves that increases morbidity
and mortality. Frailty is likely due to altered biochemical processes in the body as
demonstrated by increased concentrations of inflammatory markers such as TNF-α, IL-6,
and CRP (15). A characteristic phenotype has been described (15) and applied to the HIV
population, which demonstrates this phenotype at earlier ages than the general population
(36, 37). Significant decreases in drug clearance of 50% or greater have been demonstrated
in the frail elderly for acetaminophen (38), metoclopramide (39), and antipyrine (40)
compared to younger, healthier subjects. This increase in exposure is likely due to a
combination of decreased renal clearance and cytokine-induced down-regulation of
metabolic enzymes (41). Increased exposure likely contributes to increased toxicity of drugs
in frail patients.
The overall goal of this investigation was to use intensive PK sampling and parameters in
otherwise healthy HIV-infected population, and so frail subjects were purposefully
excluded. Only older subjects were enrolled to provide estimates of PK parameters in this
population; 55 years of age was selected at the time of study initiation. Subsequent research
and discussion in the literature suggests that HIV-infected patients may be considered
“elderly” at age 50 rather than 55 years of age (42).
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Due to the small numbers of subjects involved in this investigation, traditional statistical
comparisons have limited ability to show differences between these subjects and historic
controls. A limitation of this report is the use of historical controls rather than concomitant
enrollment of younger subjects using the same study design and analytical methods for drug
concentrations. For the extracellular drugs studied, study designs for the comparator data
used similar intensive-sampling schemes and analytical methods, and therefore statistical
comparisons are presented. For the intracellular metabolites, intensive-sampling schemes are
rarely used due to the complexity of cell processing, and analytical methodology varies
considerably from laboratory to laboratory. As data for comparison using the methods
employed here were not readily available in the literature, values are provided only as a
point of reference without formal statistical comparisons.
These data will be used to design a larger, population-based PK/PD study in HIV-infected
patients to quantify differences based on age or other patient-specific characteristics
differences, fraility being one characteristic. Population PK/PD modeling seeks to
characterize variability in drug disposition and effect in a patient population in order to
make dosing recommendations based on patient characteristics, and is a powerful and
increasingly accepted (43) tool for identifying sub-populations that may benefit from
alternative dosing strategies. Ultimately, population PK/PD modeling aims to inform
clinicians of any necessary dosing recommendations specific for older HIV-infected
populations.
In conclusion, this investigation provides rationale and background for further examination
into the area of ARV pharmacokinetics and aging. Subsequent investigations will include
the enrollment of a cohort with a broad age range and the presence of the frailty phenotype
for a population PK/PD analysis.
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Table 1
Subject Demographics by Regimen. Data presented as mean ± standard deviation, or number (percentage).
Creatinine clearance was calculated using the Cockcroft-Gault equation ( , multiplied
by 0.85 for females
1
; actual body weight was used unless the subject was >20% above their ideal body weight,
and then adjusted body weight was used).
Baseline Characteristics TFV/FTC/EFV Subjects (n = 6) TFV/FTC/ATV/RTV Subjects (n = 6)
Age (yrs) 60.7 ± 5.4 58.7 ± 1.4
Race
Caucasian 3 (50%) 3 (50%)
African American 3 (50%) 3 (50%)
Sex
Female 4 (66.7%) 2 (33.3%)
Male 2 (33.3%) 4 (66.7%)
Duration with HIV (yrs) 14.3 ± 10.3 8.4 ± 3.9
Duration on current regimen (yrs) 3.5 ± 3.65 3.4 ± 1.7
CD4+ T-cell count (cells/mm3) 683 ± 226 952 ± 455
HIV RNA <50 copies/mL 5/6 6/6
Creatinine clearance (mL/min) 69.4 ± 25.0 70.9 ± 7.46
BMI (kg/m2) 27.6 ± 5.6 32.2 ± 4.5
1
Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
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Table 2
Noncompartmental PK parameter estimates for each drug, by regimen.
Regimen Drug
terminal half-life Tmax Cmax C24hr AUC0–24hr
(hr) (hr) (ug/L) (ug/L) (hr*ug/L)
TFV/FTC/EFV
TFV 13.7 (12.4, 31.6) 3.0 (1.5, 12) 295 (223, 421) 96.8 (66.5, 112) 3.43 × 10
3 (3.05 × 103,
4.05 × 103)
FTC 6.24 (5.07, 6.57) 4.0 (2.1, 6.1) 1780 (1410, 2050) 126 (81.0, 210) 1.41 × 10
4 (1.03 × 104,
1.91 × 104)
EFV 44.9 (26.6, 68.2) 4.5 (3.0–8.0) 3403 (2840, 6120) 2180 (1460, 3620) 6.08 × 10
4 (4.60 × 104,
9.60 × 104)
TFV/FTC/ATV/RTV
TFV 11.1 (9.47, 14.1) 1.5 (1.0–2.1) 319 (275, 417) 62.1 (51.0, 80.9) 3.33 × 10
3 (2.92 × 103,
4.23 × 103)
FTC 8.53 (7.49, 9.66) 1.9 (1.0–6.0) 1840 (1470, 2130) 78.5 (62.8, 116) 1.05 × 10
4 (8.54 × 103,
12.4 × 104)
ATV 6.00 (3.75, 12.0) 2.0 (1.0–6.0) 3750 (2120, 4610) 605 (452, 1000) 3.47 × 10
4 (2.55 × 104,
3.85 × 104)
RTV 5.61 (4.18, 7.05) 2.5 (1.0–6.0) 1440 (725, 1880) 57.3 (27.2, 92.5) 6.54 × 10
3 (7.87 × 103,
1.25 × 104)
TFV: tenofovir; FTC: emtricitabine; EFV: efavirenz; ATV: atazanavir; RTV: ritonavir; Tmax: time of maximal concentration; Cmax: maximal
concentration; C24hr: concentration at the end of the 24 hr dosing interval; AUC0–24hr: area under the concentration-time curve from 0 to 24
hours
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Table 3
Median ratios for each drug, by regimen, in comparison to literature values.
TFV/FTC/EFV TFV/FTC/ATV/RTV
TFV FTC EFV TFV FTC ATV RTV
AUC0–24hr
↓ ↑ ↔ ↓ ↑ ↓ ↑
0.92 1.75 1.05 0.9 1.31 0.88 1.19
Cmax
↓ ↑ ↓ ↓ ↑ ↑ ↑
0.87 1.26 0.84 0.94 1.31 1.09 1.78
TFV: tenofovir; FTC: emtricitabine; EFV: efavirenz; ATV: atazanavir; RTV: ritonavir; Cmax: maximal concentration; AUC0–24hr: area under
the concentration-time curve from 0 to 24 hours.
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Table 4
Tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) mean concentrations over a dosing
interval and area under the concentration-time curve (AUC), by regimen.
Regimen Analyte Mean Concentration over Dosing Interval (fmol/106 cells; mean ± SD) AUC (hr•fmol/106 cells; median/IQR)
EFV
TFV-DP
128 ± 78 2410 (1450, 5030)
ATV/r 112 ± 77 2110 (1470, 2720)
EFV
FTC-TP
2830 ± 830 69400 (53500, 79000)
ATV/r 3160 ± 1190 64400 (56400, 70100)
EFV: efavirenz; ATV/r: (atazanavir/ritonavir); SD: standard deviation; IQR: interquartile range
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